A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Type of Cancer
Lymphoma

Sponsor
TG Therapeutics

Protocol Number
TGR 1202-201

To Learn More Call
(201)-510-0950